Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.

At least 15 dual-payload ADCs will be discussed.

Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.

On key measures Keynote-D77 shows subcutaneous delivery to be the equal of IV.

In first-line SCLC BNT327 looks better than Tecentriq, but data will need to be replicated outside China.

Ikena, Senti and others look to clinical presentations at AACR.

The company is abandoning ovarian and bladder, but still sees a path in endometrial cancer.